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UC the following situations are presented: ulcerative procti-
tis, left-sided colitis and pancolitis.  Conclusions: We provide 
a summary on the use of first-line therapies for clinically fre-
quent situations in patients with CD and UC. 
 Copyright © 2012 S. Karger AG, Basel 
 Introduction  
 Inflammatory bowel diseases (IBD) are characterized 
by the presence of chronic, noninfectious inflammatory 
processes of the bowel of unknown origin. Current evi-
dence suggests that, based on several genetic abnormali-
ties, a dysbalanced mucosal immune system reacts in an 
uncontrolled way to luminal antigens  [1] . The diagnosis 
of IBD is made based on a mixed picture consisting of 
symptoms, endoscopic findings, histology, radiologic ex-
ams and laboratory markers, once other causes for IBD 
such as infections have been ruled out. The two main dis-
eases are Crohn’s disease (CD) and ulcerative colitis (UC). 
CD is characterized by a transmural inflammation clas-
sically involving the terminal ileum and the proximal co-
lon. One third of the patients present only a colonic in-
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 Abstract 
 Background and Aims: Medical therapy of inflammatory 
bowel disease (IBD) is becoming more complex, given the 
increasing choice of drugs to treat Crohn’s disease (CD) and 
ulcerative colitis (UC). We aimed to summarize the current 
guidelines for first-line treatments in IBD.  Methods: An ex-
tensive literature search with focus on the guidelines of the 
European Crohn’s and Colitis Organisation for the  diagnosis 
and treatment of CD and UC was performed.  First-line treat-
ments were defined as the following drug categories: 5-ami-
nosalicylates, budesonide, systemic steroids, azathioprine, 
6-mercaptopurine, methotrexate, infliximab, adalimumab 
and certolizumab pegol. The following drug categories were 
not included: cyclosporine and tacrolimus (not yet approved 
by Swissmedic for IBD treatment).  Results: Treatment rec-
ommendations for the following clinically frequent situa-
tions are presented according to disease severity: ileocecal 
CD, colonic CD, proximal small bowel CD and perianal CD. For 
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volvement and another third have a more diffuse disease 
involving the small bowel as well as the stomach or the 
esophagus. Characteristic for CD is the transmural in-
flammation that may lead to structural complications 
such as internal or external stenoses and perianal fistulas. 
Inflammation in UC is typically limited to the colon and 
histologically to the mucosa (and submucosa). Depend-
ing on the extent, an ulcerative proctitis is discriminated 
from a left-sided colitis and a pancolitis. Both CD and UC 
can be complicated by the appearance of extra-intestinal 
manifestations (due to antigen cross-reactivity) such as 
inflammation of the eyes (uveitis and conjunctivitis), 
joints (arthritis), skin (pyoderma gangrenosum and ery-
thema nodosum) or liver (primary sclerosing cholangitis) 
 [2] .
 The choice of medical management for IBD patients 
depends on disease activity, location, extension and the 
potential involvement of other organs. The assessment of 
these items allows a tailored therapeutic approach. Treat-
ment is divided into an induction phase with the aim of 
a response or remission and then the maintenance treat-
ment which should enable the response or remission to 
continue. The following paragraphs will review the first-
line treatment choices for CD and UC, including such 
induction and maintenance therapies. The following 
drug categories are summarized under first-line thera-
pies: 5-aminosalicylates, budesonide, systemic steroids 
(prednisone and derivates), azathioprine, 6-mercaptopu-
rine, methotrexate, infliximab, adalimumab and certoli-
zumab pegol. The following second-line treatments will 
not be discussed: cyclosporine and tacrolimus. 
 Crohn’s Disease  
 Ileocecal CD 
 The ileocecal location represents the typical CD pre-
sentation. In mild to moderately active ileocecal CD 
[Crohn’s Disease Activity Index (CDAI) up to 300 points], 
budesonide 9 mg per day is the best choice to induce clin-
ical remission. Budesonide has shown its superiority to 
placebo and to mesalazine and has fewer side effects than 
systemic corticosteroids  [3] . However, in one recent study, 
the authors found that mesalazine 4.5 g per day was com-
parably efficient to budesonide to induce remission 
(69.5% for budesonide compared to 62.1% for mesalazine) 
 [4] . A CDAI drop of 100 points was observed in 89% of 
budesonide-treated patients compared to 79% of mesala-
zine-treated patients  [4] . 
 In the case of severe clinical activity (defined as CDAI 
 1 300 points) systemic corticosteroids (either predniso-
lone per os or intravenous hydrocortisone) should be ad-
ministered  [3] . In CD patients with steroid-refractory or 
steroid-dependent disease, an early introduction of anti-
TNF therapies can be beneficial. The step-up versus top-
down study showed that even treatment-naïve patients 
could benefit from this strategy  [5] . 
 Surgery is not the primary focus of this review; it 
should be considered in cases of ileocecal CD that are re-
sistant to medical therapy. 
 Maintenance therapy is usually indicated after the in-
duction of response and/or remission by corticosteroids 
as these drugs are not effective in maintaining the re-
sponse or remission, respectively, and they are further-
more associated with adverse treatment effects such as 
osteoporosis or an increased risk of infection  [6] . 
 Azathioprine (2–2.5 mg/kg/day) is the most common-
ly used drug for this situation and has proven efficacy for 
maintaining CD in remission and also for having steroid-
sparing effects  [7] . Methotrexate at weekly doses of 15 mg 
i.m. has also demonstrated efficacy in maintaining CD in 
remission  [8, 9] . 
 Colonic CD 
 Active colonic CD should be treated with systemic ste-
roids for induction of response and remission. Budesonide 
is not effective for colonic CD due to its limited action on 
the proximal colon. Azathioprine, 6-mercaptopurine or 
methotrexate can be used as steroid-sparing agents for 
maintaining the medically induced remission  [7–9] . In re-
lapsing disease, anti-TNF drugs (infliximab, adalimumab 
or certolizumab pegol) can be administered for induction 
and maintenance of remission with or without an immu-
nomodulator  [10] . The SONIC trial evaluated the efficacy 
of infliximab monotherapy, azathioprine monotherapy 
and the 2 drugs combined in 508 adults with moderate to 
severe CD who were naïve to previous treatments with ei-
ther an immunomodulator (azathioprine, 6-mercaptopu-
rine or methotrexate) or biologic therapy  [11] . Of the pa-
tients receiving combination therapy, 56.6% were in cor-
ticosteroid-free clinical remission at week 26 compared to 
44.4% who received infliximab monotherapy (p = 0.02) 
and 30.0% who received azathioprine monotherapy (p  ! 
0.001 for the comparison with combination therapy and 
p = 0.006 for the comparison with infliximab). Similar 
numerical trends were found at week 50. Whether or not 
combination therapy is associated with similar benefits in 
CD populations no longer naïve to immunomodulators 
and/or anti-TNF drugs remains to be investigated. 
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 Extensive Small Bowel CD 
 Extensive small bowel CD is defined as disease affect-
ing  1 100 cm of the small bowel and therefore carrying the 
risk of nutritional deficiencies  [12] . Treatment of exten-
sive intestinal CD is equivalent to other localization of 
CD. Systemic steroids should be used to induce clinical 
remission. The early introduction of immunomodulators 
(azathioprine, 6-mercaptopurine or methotrexate) is rec-
ommended, given their steroid-sparing effects in the 
long-term  [12] .The early introduction of anti-TNF thera-
py should also be considered, particularly for the popula-
tion with clinical indicators of poor prognosis such as a 
young age at diagnosis, an initial need for steroid therapy 
and the presence of perianal disease  [13] .
 Perianal CD  
 Perianal fistulae in CD are classified into simple and 
complex fistulae  [14] . Before deciding on specific treat-
ment for perianal CD, a pelvic MRI should be performed 
for the assessment of disease location and severity  [15] . 
The imaging will also detect the presence of perianal ab-
scesses which should be drained as soon as possible. In 
addition, a proctosigmoidoscopy should be performed as 
the presence of ongoing rectosigmoid inflammation in-
fluences the treatment success  [15] . In fact, evidence sug-
gests that fistula treatment is not successful without 
treatment of the underlying active disease  [16] . Only 
symptomatic perianal fistulae should be treated  [15] . 
 The treatment of the fistulizing CD itself is based on 
antibiotics, immunomodulators (azathioprine, 6-mer-
captopourine or methotrexate) or anti-TNF drugs. 
 Metronidazole and/or ciprofloxacin have been studied 
only in small patient series. They are effective in reducing 
symptoms but less so in inducing fistula healing  [17] . 
There are no randomized controlled trials which have 
evaluated the efficacy of azathioprine and mercaptopu-
rine on the closure of perianal fistulae as the primary end 
point in CD patients. A meta-analysis of 5 randomized 
controlled trials where closure of perianal fistulae was as-
sessed as the secondary end point favor the use of aza-
thioprine and 6-mercaptopurine for the induction and 
maintenance of perianal fistula closure  [18] .
 Infliximab was the first anti-TNF agent to demon-
strate in a randomized controlled trial effectiveness in 
inducing closure of perianal fistulae and maintaining 
this response over 1 year. An induction treatment with 5 
mg infliximab/kg at weeks 0, 2 and 6 led to a complete 
closure (defined as cessation of all drainage on 2 visits 1 
month apart) in 17/31 (55%) of patients  [19] . In the
ACCENT II trial, 33/91 (36%) of patients on infliximab 
had complete fistula closure at week 54 compared to 
19/98 (19%) on placebo (p = 0.009)  [20] . 
 In the CHARM trial (Crohn’s trial of the fully Human 
antibody Adalimumab for Remission Maintenance), CD 
patients treated with adalimumab showed a fistula remis-
sion of 30% compared to 13% on placebo (p = 0.04) at 
week 26 and a fistula remission of 33% compared to 13% 
in the placebo group (p = 0.02) at week 56 [21] .
 The Swiss FACTS survey (First Approved Certolizu-
mab Therapeutic Experience in Switzerland) demon-
strated that certolizumab pegol was associated with a 
perianal fistula closure rate of 36% at week 6 and of 55% 
closure rate at week 26  [22] . 
 Ulcerative Colitis  
 Ulcerative Proctitis  
 Active proctitis should first be treated topically. Topi-
cal mesalazine (5-aminosalicylates) was able to induce re-
mission in active proctitis and distal colitis in 31–80% 
(median 67%) of patients compared to 7–11% in patients 
treated with placebo in a meta-analysis evaluating 11 tri-
als with a total of 778 patients  [23] . It proved to be at least 
twice as effective as topical corticosteroids with regard to 
symptom improvement (OR 2.42 and 95% CI 1.72–3.41), 
endoscopic improvement (OR 1.89 and 95% CI 1.29–2.76) 
or histologic improvement (OR 2.03 and 95% CI 1.28–
3.20)  [24] . It should be applied with a dosage of 1 gram 
per day. Combining topical and oral mesalazine is more 
effective than either one only for colitis  ! 50cm from the 
anal verge  [25] , and in the case of an insufficient response 
to topical mesalazine, the combination of these with top-
ical steroids (beclomethasone dipropionate) can be ben-
eficial  [26] . Patients failing to improve on such a combi-
nation should be treated with oral prednisolone  [25] .
 Left-Sided Colitis 
 As for distal proctitis, treatment of left-sided colitis is 
based on mesalazine. The combination of oral and topical 
mesalazine therapy is recommended  [25] . A meta-analy-
sis of mesalazine showed a dose response for clinical im-
provement from  ! 2.0 g, 2.0–2.9 g and  1 3.0 g being ad-
ministered daily (p = 0.002), but not for remission  [27] . 
Thus, induction of remission of left-sided UC should be 
performed by prescribing mesalazine at a daily dosage of 
at least 3 grams. In severe left-sided UC as well as in me-
salazine-refractory moderate left-sided UC, oral steroids 
(prednisolone) are the treatment of choice for induction 
therapy. Maintenance of remission can be achieved using 
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mesalazine in lower dosages than is used for induction 
treatment  [28] . 
 Pancolitis 
 As for left-sided UC, pancolitis should be treated fol-
lowing the same rules, but systemic steroids should be 
used sooner than in left-sided colitis, depending on the 
severity. Again, the combination of both oral and topical 
mesalazine is more effective for the induction of remis-
sion  [29] . Steroids should be weaned progressively by 10 
mg per week until 20 mg and then by 5 mg per week for 
the timely recognition of steroid-dependence. In the case 
of steroid dependency, immunomodulators should be 
started. 
 In mild to moderate pancolitis, mesalazine can also be 
used as maintenance therapy  [28] . In moderate to severe 
pancolitis azathioprine proved to be more effective than 
placebo for maintaining remission  [30] . Azathioprine 
should be started when frequent relapses are observed 
while the patient is on maintenance therapy with mesala-
zine or in the case of steroid dependence.
 Acute severe colitis is a particular condition carrying 
a substantial risk for colectomy. Intravenous steroids 
should be started early and their effect should be moni-
tored closely and response assessed at 3–5 days  [25] . If an 
adequate response is not achieved under intravenous ad-
ministration of steroids, second-line treatment with inf-
liximab or cyclosporine should be initiated. Maintenance 
therapy can be achieved either by continuing infliximab 
or with azathioprine that replaces cyclosporine after the 
acute phase  [25] .
 Conclusions 
 Therapy of CD and UC is based on disease location 
and disease severity, also taking into account the pres-
ence of prognostic factors for a disabling disease course 
in the case of CD. The recommendations for induction 
therapies are summarized in  table 1 .
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Table 1.  Induction therapies for IBD depending on disease location and severity
Mild activity Moderate activity Severe activity
Crohn’s disease
Ileocaecal budesonide budesonide corticosteroids
Colonic corticosteroids corticosteroids corticosteroids
anti-TNF
Extensive small bowel corticosteroids
anti-TNF
corticosteroids
anti-TNF
corticosteroids
anti-TNF
Perianal antibiotics
surgical drainage
antibiotics
surgical drainage
anti-TNF
antibiotics
surgical drainage
anti-TNF
Ulcerative colitis
Proctitis topical aminosalicylates topical aminosalicylates topical aminosalicylates
topical steroids
Left-sided colitis topical and oral aminosalicylates topical and oral aminosalicylates
corticosteroids
topical and oral aminosalicylates
corticosteroids
Pancolitis topical and oral aminosalicylates
corticosteroids
topical and oral aminosalicylates
corticosteroids
topical and oral aminosalicylates
corticosteroids
anti-TNF
cyclosporine
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